Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q3 2022 Earnings Presentation
14 slides from Hansa Biopharma Ab's earnings presentation, Oct 20, 2022
Slide 1: Conference Call Presentation Interim Report Q3 2022
Conference Call Presentation Interim Report Q3 2022 Lund, October 20, 2022
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occ
Slide 3: Highlights for the third quarter of 2022
Positive reimbursement decisions received in Poland and Scotland; $70 million raised in non-dilutive financing; ESOT guidelines published in Transplant International Highlights for the third quarter of 2022 ü Launch activities and market access efforts in EU progressing as planned - Total Q3 revenue
Slide 4: Positive reimbursement decisions received in Poland and Scotland for Idefirix
Positive reimbursement decisions received in Poland and Scotland for Idefirix® in highly sensitized kidney transplant patients Market access has now been secured in nine European countries and procedures are ongoing in eight countries including Spain, Italy and Belgium Health Technology Assessments
Slide 5: ESOT guidelines for desensitization treatment of highly sensitized patients published
The European Society for Organ Transplantation’s (ESOT) guidelines for desensitization treatment of highly sensitized patients published in Transplant International in August 2022 Guidelines represent first international consensus on a Transplant International management pathway for highly sensitize
Slide 6: Continuous progress in our ongoing clinical programs
Continuous progress in our ongoing clinical programs Enrollment status Enrollment status Oct 19, 2022 Oct 19, 2022 Antibody Mediated Rejection Phase 2 study Anti-GBM Phase 3 study • 30/30 patients enrolled in the AMR phase 2 study • FDA has accepted Hansa’s Investigational New Drug • Enrollment comp
Slide 7: Broad clinical pipeline in transplantation and auto-immune diseases
Broad clinical pipeline in transplantation and auto-immune diseases Potentially Candidate/ Research/ Pivotal/ Marketing Project Indication Preclinical Phase 1 Phase 2 Phase 3 Authorization Marketed Next Anticipated Milestone EU: Additional agreements around EU: Kidney transplantation in highly sensi
Slide 8: Total Revenue amounted to SEK 67m in the third quarter
Total Revenue amounted to SEK 67m in the third quarter including SEK 23m in product sales Revenue (Q/Q) Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 67,1 22.7 Product sales 30,3 SEKm 26,4 43.7 Revenue recognition from 15,4 24.2 AskBio and Sarepta 19.5 4,9 9.0 4.4 5.3 5.2 6.2 0.7 Axis-Shield 0.6 1.1 0.8 0.8 Revenue
Slide 9: Continued investments in commercialization and our pipeline
Continued investments in commercialization and our pipeline SG&A expenses (Q/Q) R&D expenses (Q/Q) Net loss (Q/Q) Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 -83 -103 -80 -90 -83 -61 SEKm SEKm SEKm -68 -71 -138 -148 -154 -163 -170 -93 -91 SG&A expenses (
Slide 10: Hansa's cash runway has extended through 2024
With recent financing transaction secured Hansa’s cash runway has extended through 2024 Operating cash flow (Q/Q) Cash & short-term investments (Q/Q) Number of employees (Q/Q) Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Employees 1,215 -116 SEKm -132 -131 -129 -136 SEKm 1,007 889 754 616 145 145 141 Operating cas
Slide 11: Upcoming milestones
Upcoming milestones Milestones subject to potential COVID-19 impact Kidney U.S. Kidney transplantation U.S. transplantation GBS Phase 2 AMR Phase 2 complete complete first data read first data read out enrollment randomization out (H2 2022) (H2 2022) (H1 2023) (2023) 2022 2023 2024 Anti-GBM NiceR co
Slide 12: Q&A
Q&A Visit our new web site www.hansabiopharma.com … at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives… 12 12
Slide 13: Investor Relations
Investor Relations Contact Calendar and events Oct 20, 2022 Redeye After Work presentation, Gothenburg Klaus Sindahl Oct 21, 2022 Redeye Lunch presentation, Stockholm Head of Investor Relations Oct 26, 2022 Økonomisk Ugebrev Life Science Conference, Copenhagen Mobile: +46 (0) 709-298 269 Oct 27, 202
Slide 14: HANSAT
MZ HANSAT BIOPHARMA